Reverse myocardial remodeling according to cardiac magnetic resonance imaging in patients with heart failure and atrial fibrillation receiving dapagliflozin

Aim. To determine the effect of dapagliflozin on cardiac remodeling parameters and left ventricular mass according to cardiac magnetic resonance imaging in patients with heart failure (HF) with reduced ejection fraction (EF) and atrial fibrillation (AF).

Material and methods. The study included 60 patients with HF and AF receiving triple therapy for heart failure for at least 3 months, which were divided into two groups. Patients in the first group (1) were prescribed dapagliflozin, while patients in the second group (2) formed the comparison group. The study analyzed the following cardiac remodeling parameters and left ventricular (LV) mass measured using cardiac magnetic resonance imaging at baseline and after 6 months.

Results. Dapagliflozin led to a significant increase in LVEF from 29±6 (27-31) to 37±9 (33-40)% (p<0,001), and a decrease in the volumetric and linear dimensions of the LV and left atrium as follows: end-diastolic dimension from 70 (64-73) to 63 (60-70) mm (p<0,001), end-systolic dimension from 55±7 (52-58) to 50±7 (47-52) mm (p<0,003), end-diastolic volume from 239±50 (220-258) to 207±43 ml/m² (191-223) (p<0,001), end-systolic volume from 170±40 (155-185) to 140±33 ml/m² (p<0,001), left atrium from 48±5 (46-49) to 44±6 (42-46) mm (p<0,001), and a decrease in LV mass from 156,5 (130-180) to 109 (98-145) g (p=0,001).

Conclusion. In patients with HF with reduced LVEF and AF, dapagli­flozin therapy promotes reverse myocardial remodeling processes and increases cardiac contractility.

1. Karnik AA, Gopal DKo, Benjamin EJ, et al. Epidemiology of Atrial Fibrillation and Heart Failure: A Growing and Important Problem. Cardiology Clinics. 2019;37(2):119-29. doi:10.1016/j.ccl.2019.01.001.

2. Carlisle MA, Fudim M, DeVore AD, et al. Heart Failure and Atrial Fibrillation, Like Fire and Fury. J Am Coll Cardiol: Heart Fail. 2019;6:447-56. doi:10.1016/j.jchf.2019.03.005.

3. Prabhu S, Voskoboinik A, Kaye DM, et al. Atrial fibrillation and heart failure: cause or effect? Heart Lung Circ. 2017;26:967-74. doi:10.1016/j.hlc.2017.05.117.

4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med. 2019;381:1995-2008. doi:10.1056/NEJMoa1911303.

5. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New Engl J Med. 2020;383:1413-24. doi:10.1056/NEJMoa2022190.

6. Tereshchenko SN, Galyavich AS, Uskach TM. 2020 Clinical prac­tice guidelines for Chronic heart failure. Russian Journal of Car­diology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.

7. Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024;83(15):1444-88. doi:10.1016/j.jacc.2023.12.024.

8. Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of Dapagli­flozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mel­litus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020; 141(15):1227-34. doi:10.1161/CIRCULATIONAHA.119.044183.

9. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-17. doi:10.1007/s00125-018-4670-7.

10. Aimo A, Gaggin HK, Barison A, et al. Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2019;7(9):782-94. doi:10.1016/j.jchf.2019.06.004.

11. Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of Em­pagliflozin on Left Ventricular Volumes in Patients With Type 2 Di­abetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516-25. doi:10.1161/CIRCULATIONAHA.120.052186.

12. Schulz-Menger J, Bluemke DA, Bremerich, et al. Standardized image interpretation and post-processing in cardiovascular magnetic resonance — 2020 update: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing. J Cardiovasc Magn Reson. 2020;22(1):19. doi:10.1186/s12968-020-00610-6.

13. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35(3):569-82. doi:10.1016/s0735-1097(99)00630-0.

14. Matusik PS, Bryll A, Matusik PT, et al. Electrocardiography and cardiac magnetic resonance imaging in the detection of left ven­tricular hypertrophy: the impact of indexing methods. Kardiol Pol. 2020;78(9):889-98. doi:10.33963/KP.15464.

15. Singh JSS, Mordi IR, Vickneson K, et al. Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care. 2020;43(6):1356-9. doi:10.2337/dc19-2187.

16. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. EMPA-TROPISM (ATRU-4) Investigators. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(3):243-55. doi:10.1016/j.jacc.2020.11.008.

17. Verma S, Mazer CD, Yan AT, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140(21):1693-702. doi:10.1161/CIRCULATIONAHA.119.042375.

18. Chen J, Jiang C, Guo M, et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024;23(1):2. doi:10.1186/s12933-023-02042-9.